Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Governance Other
confidence 85%
filed 2026-08-20
The filing discloses a 1-for-15 reverse stock split of bioAffinity Technologies' common stock, approved by stockholders at the April 30, 2026 annual meeting and effectuated via Certificate of Amendment filed August 20, 2026. The reverse split is a governance/capital structure event intended to bring the company into compliance with Nasdaq's minimum bid price requirement. While not a named governance category (exec appointment/departure, auditor change, shareholder vote results), this is clearly a material governance matter affecting all shareholders' holdings and the company's continued listing compliance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-08-20
The filing discloses entry into a non-binding Letter of Intent (LOI) on August 19, 2026, pursuant to which Amaze Holdings proposes to acquire a 19.99% minority stake in C2 Capital Group for $3,000,000 in cash, with contingent put options for up to 1,000,000 additional shares. Although non-binding, Item 1.01 explicitly classifies this as "Entry into a Material Definitive Agreement," and the transaction contemplates a strategic investment and board seat, making it material M&A activity subject to 8-K disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-20
The 8-K discloses BTCS Inc.'s financial results for Q2 2026 (quarter ended June 30, 2026) via a press release furnished as Exhibit 99.1. The filing explicitly states under Item 7.01 that "BTCS Inc. (the 'Company') issued a press release announcing its financial results for the quarter ended June 30, 2026." The press release reports total revenues of $2.4 million, gross profit of $1.5 million at 61% margin, and a net loss of $34.9 million, along with detailed segment performance and balance sheet metrics. This is a standard quarterly earnings disclosure material to investors.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 75%
filed 2026-08-20
The filing discloses a share repurchase program under which Eightco repurchased approximately 14 million shares in the past two weeks under its previously announced $125 million share repurchase program. While share repurchases are technically a form of capital return to shareholders (similar to dividends), the primary focus of the press release is an operational update on the company's treasury holdings and strategic investments. However, the repurchase activity is explicitly highlighted as a material capital allocation decision, making this a dividend_distribution event (which encompasses share repurchases and returns of capital).
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-20
EX-99.1
This press release announces the completion of a US$4.0 million private placement of 4.0 million ordinary shares at US$1.00 per share—an unregistered equity issuance by a small-cap public company. The transaction is a classic dilutive equity raise: common shares issued in a private placement exempt from Securities Act registration, with no warrants or convertibles. The 160% premium to the prior closing price and the capital infusion are material to investors assessing the company's financial position and ownership structure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-20
Item 3.01
Ocean Power Technologies received a notice from NYSE Regulation on August 14, 2026, stating non-compliance with continued listing standards under Section 1007 of the NYSE American Company Guide due to failure to timely file its Form 10-K by the extended due date of August 13, 2026. Although the Company cured the deficiency by filing the Form 10-K on August 19, 2026, the Item 3.01 disclosure itself documents the delisting notice and the cure period framework, which is the hallmark of delisting_risk classification. The materiality is clear: a delisting notice directly threatens the registrant's continued listing status and would significantly affect investor assessment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-08-20
Item 5.01 discloses a Stock Purchase Agreement dated August 20, 2026, whereby Ya Deng purchased 19,300,000 shares (83.2% of voting rights on a fully-diluted basis) from Zonghan Wu at $0.015 per share, resulting in a change of control of Rocky Mountains Group Ltd. This constitutes a material acquisition or change of control event. While Item 5.02 also documents the concurrent departure of Zonghan Wu and appointment of Ya Deng, the central disclosed transaction is the change of control through the share purchase, making ma_activity the primary classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-20
Protagenic announced receipt of FDA written responses to its Type B pre-IND meeting request for PT00114, with FDA raising no objections to the planned Phase 1 program design, CMC, and nonclinical packages. The company plans to submit an IND before end of 2026 and target first patient dosing in H1 2027. This is a material regulatory milestone for a clinical-stage biopharmaceutical company advancing its lead product candidate, but does not fit the specific categories of earnings, M&A, impairment, litigation, or other named event types—it is a significant operational/regulatory development in the drug development pathway.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-20
Newton Golf Company entered into a Securities Purchase Agreement on August 14, 2026 for a private placement of common stock with up to $5,000,000 in aggregate proceeds (first tranche of $1,000,000 closed immediately). The shares are unregistered securities sold pursuant to Section 4(a)(2) and Regulation D exemptions to accredited investors. This is a classic dilutive equity issuance disclosed under Item 1.01 and Item 3.02, representing a material capital raise that dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-20
The filing discloses that RenovoRx received a Nasdaq non-compliance notice on December 31, 2025 for failing the Minimum Bid Price Requirement (closing bid below $1.00 for 30 consecutive business days), and subsequently regained compliance on August 20, 2026 when the stock closed at $1.00 or greater for ten consecutive business days. This is a delisting-risk event—the company was at risk of delisting and has now cured the deficiency. The materiality is clear: listing compliance directly affects investor access and trading liquidity.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-20
The filing discloses Flux Power's fiscal fourth quarter and full-year 2026 financial results under Item 2.02, with a press release (Exhibit 99.1) reporting revenue of $8.2 million for Q4 and $42.1 million for the full year, along with operating and net losses. This is a standard earnings release announcement with detailed financial statements and management commentary.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-20
The 8-K discloses quarterly financial results for Q2 2026 under Item 2.02 (Results of Operations and Financial Condition). The press release reports significant operational and financial metrics including 510% sequential revenue growth, improved gross margins of 97.7%, 48% improvement in operating loss year-over-year, and 58% narrowing of net loss. The filing also highlights commercial milestones including the launch of REZENOPY™ as a second commercial product. This is a standard earnings release disclosure material to investors assessing the company's financial performance and operational progress.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-20
EX-99.1
This exhibit is a press release announcing Intchains Group Limited's unaudited financial results for the first half of 2026 (H1 2026) ended June 30, 2026. The document discloses revenue of RMB11.1 million, a net loss of RMB148.9 million, and basic and diluted net loss per ordinary share of RMB1.22, representing a significant deterioration from H1 2025 results. The disclosure is material as it reports substantial operating losses, a 93.7% revenue decline, and cryptocurrency fair-value losses that would affect a reasonable investor's assessment of the company's financial condition and performance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-20
The Board appointed two new directors, Mr. K. Brice "Rick" Toussaint and Mr. Bin Zhou, effective immediately on August 18, 2026. Both were also appointed to multiple board committees (Audit, Compensation, and Nominating & Corporate Governance), with Toussaint as Audit Committee Chair and Zhou as Compensation Committee Chair. This is a material governance event affecting board composition and committee leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-20
Item 5.02
The Board of Directors approved the appointment of James Liddy as a director of the Company, effective immediately on August 19, 2026. This is a clear director appointment disclosed under Item 5.02, which is material to investors as board composition affects governance and oversight. The filing explicitly states there are no conflicting arrangements or related-party transactions, indicating a straightforward appointment event.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-08-20
The filing discloses adjustment of warrant exercise prices and share counts following a 45-for-1 share consolidation effected in August 2026. The warrant adjustments—reducing exercise price to $3.80 per share and increasing shares issuable to approximately 3,193,862—reflect anti-dilution provisions triggered by the consolidation and prior offerings in May, July, and August 2026. While the primary event is a technical warrant adjustment rather than a new issuance, the disclosure concerns dilutive equity instruments (warrants) and their adjustment mechanics, which materially affect shareholder dilution and capital structure.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-08-20
The filing discloses a new Executive Employment Agreement with CEO David Boulette dated August 17, 2026, replacing his prior agreement. The agreement specifies material compensatory arrangements including: base salary of $800,000 with automatic 10% annual increases, eligibility for annual bonuses, and up to 1,000,000 shares of Series A Convertible Preferred Stock (convertible into 150 million common shares) contingent on performance milestones. The filing also details severance provisions ($5,000,000 lump-sum payment upon termination without Cause or for Good Reason) and the Certificate of Designation for the Series A Preferred Stock with conversion, liquidation preference, and voting rights. This is a comprehensive compensatory arrangement disclosure under Item 5.02(e).
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-08-20
The 8-K discloses preliminary unaudited financial results for Q4 FY2026 (quarter ended June 30, 2026) via press release filed as Exhibit 99.1 under Item 2.02. The filing highlights record quarterly revenue of $8.2 million, gross profit of $1.3 million (86% increase), and reinstatement of a $57 million DOE grant. While the results include material operational and regulatory developments, the core disclosure mechanism and primary Item classification is an earnings release.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-08-20
This 8-K discloses a joint investor update call held on August 20, 2026, by Hennessy Capital Investment Corp. VII and ONE Nuclear Energy regarding their pending business combination transaction. The filing explicitly references the Business Combination Agreement dated October 22, 2025, and notes that the SEC declared the Registration Statement effective on August 3, 2026, with the definitive Proxy Statement mailed to shareholders for a vote on the Business Combination. The exhibits include an investor presentation and call transcript discussing the combined company's strategy, site portfolio, and financial projections, all central to the M&A transaction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-08-20
The filing discloses entry into a Strategic Partnership Agreement with Shanghai Launch Automotive Technology Co., Ltd. on August 14, 2026, under Item 1.01 (Entry into a Material Definitive Agreement). The agreement establishes a manufacturing and contract-engineering partnership with up to RMB 300,000,000 in consideration, including cash payments and warrant issuances. While this is a partnership rather than a traditional M&A transaction, it represents a material strategic arrangement that would affect investor assessment of the company's manufacturing capabilities and capital structure. Item 3.02 also discloses concurrent unregistered warrant issuance (3,369,629 warrants worth RMB 50,000,000), which is a dilutive equity issuance tied to the partnership.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-20
The filing discloses results of Interpace Biosciences' 2026 annual meeting of stockholders held on August 20, 2026, with voting outcomes on seven proposals including approval of an amended certificate of incorporation, reverse stock split authorization, equity and employee stock purchase plans, director elections, executive compensation advisory vote, and auditor ratification. This is a classic Item 5.07 shareholder vote results disclosure with detailed vote tallies for each proposal.
View raw filing on EDGAR →
6-K
Periodic Interim
confidence 95%
filed 2026-08-20
This is an unaudited interim consolidated financial report for the six-month period ended June 30, 2026, comprising balance sheets, statements of operations, changes in stockholders' equity, cash flows, and accompanying notes. The filing explicitly states "unaudited condensed interim consolidated statements" and covers a half-year period (January 1 – June 30, 2026), making it a periodic interim report rather than a discrete event or earnings press release. The financial statements show a net loss of $7.9 million for the period and negative stockholders' equity of $81.6 million as of June 30, 2026, which are material to investors' assessment of the registrant's financial condition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-20
Item 5.02
Taryn McHarg was appointed as Chief Financial Officer, effective upon the retirement of incumbent CFO Mark Haushill on March 31, 2027. Haushill will transition to a Senior Advisor role to provide continuity during the transition.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-20
Item 8.01
This 8-K discloses the issuance of commercial mortgage pass-through certificates (BANK5 2026-5YR24) by Morgan Stanley Capital I Inc., representing a securitization of a $270.1 million pool of 35 commercial, multifamily, and manufactured housing mortgage loans. The filing describes the creation of multiple certificate classes backed by these mortgage loans, with a closing date of August 31, 2026. This constitutes a material debt issuance—a new direct financial obligation created through the securitization structure, distinct from a typical bond issuance but economically equivalent in creating investor claims on cash flows from the underlying mortgage pool.
View raw filing on EDGAR →
6-K
M&A activity
confidence 75%
filed 2026-08-20
Cosan discloses that it is "evaluating alternatives for the sale of a portion of its equity interest in Rumo S.A." and that potential buyers are submitting "binding proposals." This constitutes a material acquisition or disposition activity (M&A activity) under Item 1.01/1.02 equivalent. Although no final decision has been made, the company is actively in the binding-proposal phase of a potential divestiture of a significant stake, which would materially affect investor assessment of the company's capital structure and deleveraging strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-20
EX-99.1
Blue Moon announces receipt of critical regulatory permits and approvals for its Springer tungsten project in Nevada: transfer of the Water Pollution Control Permit and Reclamation Permit into the Company's name, posting of the reclamation closure bond, and formal approval of the Notice of Construction for the tailings storage facility. These authorizations enable the Company to commence construction activities on schedule toward a late 2027 startup. This is a material operational milestone—the removal of a key regulatory hurdle to project development—but does not fit the specific event categories (M&A, impairment, litigation, etc.); it is a regulatory approval enabling a strategic project to advance.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-08-20
Item 8.01
News Corporation discloses daily share repurchase activity under its $1 billion Repurchase Program authorized July 15, 2025. The exhibits show purchases of approximately 11.08 million Class A shares and 58,482 Class B shares on August 20, 2026, totaling ~$284.8 million in consideration. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category as a return-of-capital mechanism, distinct from operational or financial events.
View raw filing on EDGAR →
6-K
Governance Other
confidence 75%
filed 2026-08-20
EX-99.1
This disclosure reports receipt of an independent evaluator's report (from EY Consultores Limitada) on an Equity Support Agreement (ESA) with parent company Empresas Copec S.A., submitted to shareholders for approval at an Extraordinary Shareholders' Meeting. The filing is a governance matter involving shareholder approval of a material transaction with a related party, but it is not itself a shareholder vote result (which would be `shareholder_vote_results`); rather, it is a procedural governance disclosure providing shareholders with the independent evaluator's assessment prior to voting. The materiality of the underlying ESA transaction and the governance process around it make this material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-20
Item 5.02
The filing discloses the appointment of François Vachon as Chief Executive Officer (effective August 13, 2026) and as a Board member (effective August 18, 2026), along with the appointment of Kurtis W. Winn to additional officer roles. While Lin Li's resignation as CEO and director is also disclosed, the principal action centers on the appointment of a new CEO with detailed compensation terms ($7,000–$10,000 monthly base salary, one-year term) and extensive responsibilities for governance, compliance, manufacturing oversight, and capital raising. This is a material executive appointment affecting the registrant's leadership structure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-08-20
Item 8.01
Pitney Bowes announced the commencement of cash tender offers to purchase up to $50 million aggregate principal amount of its outstanding 6.70% Notes due 2043 and 5.250% Medium-Term Notes due 2037. While this is technically a debt repurchase rather than issuance, it represents a material modification of the company's direct financial obligations and capital structure. The tender offer is a significant financial event affecting the company's debt portfolio and liquidity position, warranting disclosure under Item 8.01 as a material event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-20
Item 8.01
Standard Nuclear announced execution of a binding fuel supply agreement with Radiant Industries for multi-metric-ton TRISO fuel deliveries through 2031. This is a material commercial contract securing multi-year customer demand for the company's core product, but it does not fit the specific categories of M&A activity, debt issuance, or other named financial/operational events. The agreement represents a significant operational and strategic milestone for an early-stage advanced nuclear fuel producer, making it a material operational event.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-20
Item 3.01
BullFrog AI received notice from Nasdaq on August 18, 2026, that while it has not regained compliance with the Minimum Bid Price Requirement (closing bid price below $1.00 per share), it has been granted a second 180-calendar-day compliance period until February 8, 2027. The filing explicitly states that if the Company does not regain compliance by that date, "the Company's listed securities will be subject to delisting." This is a direct delisting risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-20
EX-99.1
This press release announces a multi-year global partnership between Prenetics' IM8 brand and actress Lily Collins as a Global Ambassador and shareholder. While the disclosure includes forward-looking revenue guidance ($220+ million for FY 2026, $400+ million for FY 2027), the primary event is the strategic partnership and brand ambassador arrangement—a material operational and marketing development for the company's growth strategy. The guidance is secondary context supporting the partnership's significance, not the principal disclosure. This is a strategic business partnership that would affect investor assessment of the company's market reach and growth trajectory.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-20
Item 5.02
The filing discloses the appointment of Michael D. Stein to the Board of Governors on August 19, 2026, to fill a vacancy. The principal action is a person taking a governance role, with assignment to three board committees (risk management, audit, and fixed assets). This is a clear executive appointment under Item 5.02 and is material to investors as board composition affects governance and oversight.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-20
Item 3.02
Rise Companies Corp. qualified 4,275,000 shares of Class B Common Stock for sale in a continuous offering under Regulation A (Rule 251(d)(3)), with an expected offering period through September 23, 2028. This unregistered equity issuance will dilute existing shareholders and raise capital for the company.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 75%
filed 2026-08-20
EX-99.1
The exhibit announces the appointment of Finn Age Hänsel as President, Rest of World & Chief Strategy Officer and Adrian Frenzel as Global Chief Operating Officer. While the document also discusses the amended earnout agreement and integration strategy, the principal disclosed actions are executive appointments to senior leadership roles. These appointments are material to investors as they reflect significant organizational restructuring and leadership changes following the Sanity acquisition.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 97%
filed 2026-08-20
Item 2.03
Corebridge Financial issued $750 million in aggregate principal amount of 5.900% Senior Notes due 2036 pursuant to an Underwriting Agreement dated August 17, 2026 and a Ninth Supplemental Indenture executed on August 20, 2026. The company intends to use the proceeds to refinance existing debt obligations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 88%
filed 2026-08-20
Item 2.03
Suja Life entered into an Amended and Restated Credit Agreement with JPMorgan Chase Bank that modifies its existing credit facility originally dated August 23, 2021. The amendment reduces the borrowing spread and lowers the Company's cost of capital, with the new interest rate terms set at Term SOFR plus 1.75%-2.25% based on leverage ratio, resulting in expected 2026 total interest expense improvement to $18.0 million.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-20
Item 1.01
Blue Owl Technology Finance Corp. entered into a $250 million revolving credit facility with Natixis as administrative agent on August 14, 2026, with a 10-year maturity and interest at SOFR plus 2.25%, to finance asset origination and acquisition.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 97%
filed 2026-08-20
Item 2.03
Blue Owl Technology Finance Corp. issued an additional $400 million aggregate principal amount of 6.500% notes due 2029 on August 20, 2026, bringing total outstanding notes to $900 million, with net proceeds to be used to pay down existing senior secured revolving credit facility indebtedness.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-20
Item 1.01
Senti Holdings, a wholly owned subsidiary, issued and sold $4.0 million in aggregate principal amount of Senior Secured Convertible Notes to Celadon Partners SPV 24 pursuant to a Securities Purchase Agreement dated April 27, 2026, creating a new direct financial obligation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-08-20
Item 2.03
An entity affiliated with Celadon would merge with and into Senti Holdings, with contingent value rights worth up to $60 million tied to regulatory and sales milestones for SENTI-202, constituting a material acquisition and change of control transaction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-20
Item 1.01
James Hardie entered into a definitive Share Purchase Agreement to sell its European fibre gypsum and cement-bonded products business (Fermacell) to Holcim for €840 million (~$980 million USD), with expected closure in H1 2027. The transaction includes closure of the European fiber cement business and is expected to materially reshape the company's portfolio, accelerate deleveraging, and fund a $250 million share repurchase program.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-20
Item 5.07
This is a clear disclosure of shareholder vote results from RCI Hospitality Holdings' Annual Meeting of Stockholders held on August 20, 2026. The filing reports voting outcomes on three matters: election of six directors (Item 1), ratification of CBIZ CPAs P.C. as independent auditor (Item 2), and approval of a non-binding advisory resolution on executive compensation (Item 3), with detailed vote tallies for each. This is a quintessential Item 5.07 disclosure and material to investors as it reflects governance decisions and shareholder approval of key corporate matters.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-20
Item 8.01
The filing discloses a declaration of a quarterly cash dividend of $0.15 per share payable on September 17, 2026, to stockholders of record as of September 3, 2026. This is a routine but material dividend distribution to shareholders, clearly fitting the dividend_distribution event type. The press release confirms the Board's declaration and the CEO's comment about continuing the quarterly dividend reinforces this is a regular capital distribution to shareholders.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-20
Item 5.02
Ana Dutra was elected as an independent director of Tredegar Corporation and appointed to the Board's Executive Compensation Committee, effective August 17, 2026. The appointment strengthens the Board's governance and oversight capabilities.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 92%
filed 2026-08-20
Methanex announced that Natgasoline LLC (50% joint venture) has priced a $290.95 million issuance of tax-exempt bonds with a 4.75% coupon, maturing in 2046, to refinance existing 2018 municipal bonds. This constitutes creation of a new direct financial obligation for the joint venture in which Methanex holds a material equity interest, and the refinancing activity is disclosed as a material corporate event affecting the entity's capital structure and cash flow flexibility.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-20
EX-99.1
This press release announces positive preliminary Phase 1 clinical trial data for ACI-19764, an NLRP3 inhibitor. The disclosure reports safety, tolerability, pharmacokinetics, and pharmacodynamic results from a first-in-human study, including confirmed brain penetration and dose-dependent IL-1beta inhibition. While this is a clinical development milestone rather than a discrete event like M&A or executive change, it represents material operational progress for a clinical-stage biopharmaceutical company that would affect a reasonable investor's assessment of the company's pipeline and therapeutic potential.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-08-20
HSBC granted conditional awards to employees and former employees for 286,184 ordinary shares under the HSBC Share Plan 2011 on 19 August 2026. The announcement discloses compensatory arrangements including vesting schedules (3–5 years depending on employee category), retention periods, clawback provisions, and performance targets—all hallmarks of executive and employee equity compensation arrangements subject to Item 5.02(e) disclosure requirements.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-20
EX-99.1
Vox Royalty has entered into a binding Royalty Sale and Purchase Agreement to acquire two Australian royalty interests (Kalman and Sylvania) for total cash consideration of up to A$3.4 million. This is a material acquisition of assets that expands the company's royalty portfolio and represents a discrete M&A transaction subject to customary conditions precedent, consistent with Item 1.01 (Material Agreements) or Item 2.01 (Completion of Acquisition or Disposition of Assets) disclosure requirements.
View raw filing on EDGAR →